Objective：To systematically evaluate the efficacy and acceptability of paclitaxel plus cisplatin（PC） and paclitaxel plus ox－aliplatin（PO） for treating patients with advanced non-small cell lung cancer. Methods：PubMed，Cochrane Library，Embase，Web of Science，CNKI，CBM-disc，VIP and WanFang Data were searched up to October 2013. Randomized controlled trials（RCTs） of PC versus PO for trearing advanced non-small cell lung cancer were extracted，reviewed，and validated according to the study protocol by two reviewers independently. Results：Fourteen RCTs involving 929 patients were included. The pooled results indicated that PC and PO had comparable efficacy concerning overall response rate（RR=1.10，95%CI=0.91 to 1.32，P=0.33），disease control rate（RR=1.02，95%CI=0.93 to 1.11，P=0.65），one-year survival rate（RR=1.03，95%CI=0.81 to 1.31，P=0.84） and alopecia rate（RR=0.96，95%CI=0.76 to 1.22，P=0.75）. Leucopenia，gastrointestinal and kidney toxicity were more serious in PC（P<0.05）. Neuritis toxicity was more serious in PO（P<0.05）. Conclusion：PO had the same efficacy as PC in treating mid-advanced non-small cell lung cancer，but its toxic effect is milder，and could be considered as supernormal chemotherapy besides the conventional guideline and norm. Simultane－ously，research advances in this field should be continued to make the results more reasonable.